Gilead’s Kite doubles down on Arcellx’s blood cancer cell therapies with $285M

Gilead’s cell therapy unit Kite wants more of what it initially got from Arcellx last December, buying $200 million worth of equity in Arcellx and doling out $85 million in cash to expand their partnership.

The deal arrives three months after the FDA…
Click here to view original post